• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

局部肺腺癌中 TCR 库的肿瘤内异质性:与预测的新抗原异质性和术后复发的关联。

TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence.

机构信息

Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.

出版信息

Cancer Discov. 2017 Oct;7(10):1088-1097. doi: 10.1158/2159-8290.CD-17-0256. Epub 2017 Jul 21.

DOI:10.1158/2159-8290.CD-17-0256
PMID:28733428
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5628137/
Abstract

Genomic intratumor heterogeneity (ITH) may be associated with postsurgical relapse of localized lung adenocarcinomas. Recently, mutations, through generation of neoantigens, were shown to alter tumor immunogenicity through T-cell responses. Here, we performed sequencing of the T-cell receptor (TCR) in 45 tumor regions from 11 localized lung adenocarcinomas and observed substantial intratumor differences in T-cell density and clonality with the majority of T-cell clones restricted to individual tumor regions. TCR ITH positively correlated with predicted neoantigen ITH, suggesting that spatial differences in the T-cell repertoire may be driven by distinct neoantigens in different tumor regions. Finally, a higher degree of TCR ITH was associated with an increased risk of postsurgical relapse and shorter disease-free survival, suggesting a potential clinical significance of T-cell repertoire heterogeneity. The present study provides insights into the ITH of the T-cell repertoire in localized lung adenocarcinomas and its potential biological and clinical impact. The results suggest that T-cell repertoire ITH may be tightly associated to genomic ITH and disease relapse. .

摘要

肿瘤内基因组异质性(ITH)可能与局部肺腺癌手术后的复发有关。最近,通过产生新抗原的突变,被证明可以通过 T 细胞反应改变肿瘤的免疫原性。在这里,我们对 11 例局部肺腺癌的 45 个肿瘤区域进行了 T 细胞受体(TCR)测序,观察到 T 细胞密度和克隆性存在明显的肿瘤内差异,大多数 T 细胞克隆局限于单个肿瘤区域。TCR ITH 与预测的新抗原 ITH 呈正相关,表明 T 细胞库的空间差异可能是由不同肿瘤区域中不同的新抗原驱动的。最后,较高程度的 TCR ITH 与手术后复发风险增加和无病生存期缩短相关,提示 T 细胞库异质性具有潜在的临床意义。本研究提供了对局部肺腺癌中 T 细胞库 ITH 及其潜在生物学和临床影响的深入了解。结果表明,T 细胞库 ITH 可能与基因组 ITH 和疾病复发密切相关。

相似文献

1
TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence.局部肺腺癌中 TCR 库的肿瘤内异质性:与预测的新抗原异质性和术后复发的关联。
Cancer Discov. 2017 Oct;7(10):1088-1097. doi: 10.1158/2159-8290.CD-17-0256. Epub 2017 Jul 21.
2
TCR repertoire intratumor heterogeneity of CD4 and CD8 T cells in centers and margins of localized lung adenocarcinomas.局部肺腺癌中心和边缘处 CD4 和 CD8 T 细胞 TCR 库的肿瘤内异质性。
Int J Cancer. 2019 Feb 15;144(4):818-827. doi: 10.1002/ijc.31760. Epub 2018 Sep 29.
3
Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing.多区域测序描绘的局限性肺腺癌肿瘤内异质性。
Science. 2014 Oct 10;346(6206):256-9. doi: 10.1126/science.1256930.
4
Analysis of Immune Intratumor Heterogeneity Highlights Immunoregulatory and Coinhibitory Lymphocytes as Hallmarks of Recurrence in Stage I Non-Small Cell Lung Cancer.分析肿瘤内免疫异质性突出了免疫调节和共抑制淋巴细胞作为 I 期非小细胞肺癌复发的标志。
Mod Pathol. 2023 Jan;36(1):100028. doi: 10.1016/j.modpat.2022.100028.
5
Cold and heterogeneous T cell repertoire is associated with copy number aberrations and loss of immune genes in small-cell lung cancer.冷且异质性的 T 细胞受体库与小细胞肺癌中的拷贝数异常和免疫基因缺失有关。
Nat Commun. 2021 Nov 17;12(1):6655. doi: 10.1038/s41467-021-26821-8.
6
DNA methylation intratumor heterogeneity in localized lung adenocarcinomas.局部肺腺癌中的DNA甲基化肿瘤内异质性
Oncotarget. 2017 Mar 28;8(13):21994-22002. doi: 10.18632/oncotarget.15777.
7
Evolution of Genomic and T-cell Repertoire Heterogeneity of Malignant Pleural Mesothelioma Under Dasatinib Treatment.达沙替尼治疗下恶性胸膜间皮瘤基因组和 T 细胞受体库异质性的演变。
Clin Cancer Res. 2020 Oct 15;26(20):5477-5486. doi: 10.1158/1078-0432.CCR-20-1767. Epub 2020 Aug 14.
8
Analysis of genomic and immune intratumor heterogeneity in linitis plastica via multiregional exome and T-cell receptor sequencing.通过多区域外显子组和 T 细胞受体测序分析皮革胃中的肿瘤基因组和免疫异质性。
Mol Oncol. 2023 Aug;17(8):1531-1544. doi: 10.1002/1878-0261.13381. Epub 2023 Mar 7.
9
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade.克隆性新抗原引发T细胞免疫反应性以及对免疫检查点阻断的敏感性。
Science. 2016 Mar 25;351(6280):1463-9. doi: 10.1126/science.aaf1490. Epub 2016 Mar 3.
10
Significant differences in T cell receptor repertoires in lung adenocarcinomas with and without epidermal growth factor receptor mutations.肺腺癌中存在表皮生长因子受体突变与无突变的 T 细胞受体谱系存在显著差异。
Cancer Sci. 2019 Mar;110(3):867-874. doi: 10.1111/cas.13919. Epub 2019 Feb 16.

引用本文的文献

1
Neoantigen-driven personalized tumor therapy: An update from discovery to clinical application.新抗原驱动的个性化肿瘤治疗:从发现到临床应用的最新进展
Chin Med J (Engl). 2025 Sep 5;138(17):2057-2090. doi: 10.1097/CM9.0000000000003708. Epub 2025 Aug 4.
2
Pre-treatment peripheral blood TCR repertoire as a predictor of response in patients with NSCLC treated with immunochemotherapy.治疗前外周血TCR库作为接受免疫化疗的非小细胞肺癌患者反应的预测指标。
BMC Cancer. 2025 Jul 1;25(1):1105. doi: 10.1186/s12885-025-14523-z.
3
Clinical and Fundamental Research Progressions on Tumor-Infiltrating Lymphocytes Therapy in Cancer.

本文引用的文献

1
Image Analysis-based Assessment of PD-L1 and Tumor-Associated Immune Cells Density Supports Distinct Intratumoral Microenvironment Groups in Non-small Cell Lung Carcinoma Patients.基于图像分析的PD-L1及肿瘤相关免疫细胞密度评估支持非小细胞肺癌患者不同的肿瘤内微环境分组
Clin Cancer Res. 2016 Dec 15;22(24):6278-6289. doi: 10.1158/1078-0432.CCR-15-2443. Epub 2016 Jun 1.
2
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.阿替利珠单抗用于接受铂类化疗后病情进展的局部晚期和转移性尿路上皮癌患者:一项单臂、多中心、2期试验。
Lancet. 2016 May 7;387(10031):1909-20. doi: 10.1016/S0140-6736(16)00561-4. Epub 2016 Mar 4.
3
癌症中肿瘤浸润淋巴细胞疗法的临床与基础研究进展
Vaccines (Basel). 2025 May 14;13(5):521. doi: 10.3390/vaccines13050521.
4
Outcomes of Radium-223 and Stereotactic Ablative Radiotherapy Versus Stereotactic Ablative Radiotherapy for Oligometastatic Prostate Cancers: The RAVENS Phase II Randomized Trial.镭-223与立体定向消融放疗对比立体定向消融放疗治疗寡转移前列腺癌的疗效:RAVENS II期随机试验
J Clin Oncol. 2025 Jun 20;43(18):2059-2068. doi: 10.1200/JCO-25-00131. Epub 2025 May 7.
5
Tumor Heterogeneity and the Immune Response in Non-Small Cell Lung Cancer: Emerging Insights and Implications for Immunotherapy.非小细胞肺癌中的肿瘤异质性与免疫反应:免疫治疗的新见解及意义
Cancers (Basel). 2025 Mar 19;17(6):1027. doi: 10.3390/cancers17061027.
6
Novel immune drug combination induces tumour microenvironment remodelling and reduces the dosage of anti-PD-1 antibody.新型免疫药物组合可诱导肿瘤微环境重塑并降低抗PD-1抗体的剂量。
Sci Rep. 2025 Mar 15;15(1):8956. doi: 10.1038/s41598-025-87344-6.
7
A subunit vaccine Ag85A-LpqH focusing on humoral immunity provides substantial protection against tuberculosis in mice.一种聚焦于体液免疫的亚单位疫苗Ag85A-LpqH为小鼠提供了对结核病的显著保护。
iScience. 2024 Dec 20;28(1):111568. doi: 10.1016/j.isci.2024.111568. eCollection 2025 Jan 17.
8
Systematic evaluation of intratumoral and peripheral BCR repertoires in three cancers.三种癌症中肿瘤内和外周B细胞受体库的系统评估
Elife. 2025 Jan 20;13:RP89506. doi: 10.7554/eLife.89506.
9
Programmed cell death pathways in lung adenocarcinoma: illuminating tumor drug resistance and therapeutic opportunities through single-cell analysis.肺腺癌中的程序性细胞死亡途径:通过单细胞分析揭示肿瘤耐药性和治疗机会。
Discov Oncol. 2024 Dec 23;15(1):828. doi: 10.1007/s12672-024-01736-0.
10
Proteomic profile of the antibody diversity in circulating extracellular vesicles of lung adenocarcinoma.肺腺癌循环细胞外囊泡中抗体多样性的蛋白质组学特征。
Sci Rep. 2024 Nov 14;14(1):27953. doi: 10.1038/s41598-024-78955-6.
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade.克隆性新抗原引发T细胞免疫反应性以及对免疫检查点阻断的敏感性。
Science. 2016 Mar 25;351(6280):1463-9. doi: 10.1126/science.aaf1490. Epub 2016 Mar 3.
4
Accurate pan-specific prediction of peptide-MHC class II binding affinity with improved binding core identification.通过改进结合核心识别实现对肽-MHC II类结合亲和力的准确泛特异性预测。
Immunogenetics. 2015 Nov;67(11-12):641-50. doi: 10.1007/s00251-015-0873-y. Epub 2015 Sep 29.
5
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.纳武利尤单抗对比多西他赛治疗晚期非鳞状非小细胞肺癌
N Engl J Med. 2015 Oct 22;373(17):1627-39. doi: 10.1056/NEJMoa1507643. Epub 2015 Sep 27.
6
T-cell receptor profiling in cancer.癌症中的T细胞受体分析
Mol Oncol. 2015 Dec;9(10):2063-70. doi: 10.1016/j.molonc.2015.09.003. Epub 2015 Sep 15.
7
Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes.I类HLA基因中癌症相关体细胞突变的综合分析
Nat Biotechnol. 2015 Nov;33(11):1152-8. doi: 10.1038/nbt.3344.
8
Pembrolizumab versus Ipilimumab in Advanced Melanoma.帕博利珠单抗对比伊匹单抗用于晚期黑色素瘤。
N Engl J Med. 2015 Jun 25;372(26):2521-32. doi: 10.1056/NEJMoa1503093. Epub 2015 Apr 19.
9
The future of immune checkpoint therapy.免疫检查点疗法的未来。
Science. 2015 Apr 3;348(6230):56-61. doi: 10.1126/science.aaa8172.
10
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy.程序性死亡受体配体1(PD-L1)表达作为癌症免疫治疗中的预测生物标志物
Mol Cancer Ther. 2015 Apr;14(4):847-56. doi: 10.1158/1535-7163.MCT-14-0983. Epub 2015 Feb 18.